Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More
DISHMAN PHARMA | DR. REDDYS LAB | DISHMAN PHARMA/ DR. REDDYS LAB |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | 34.3 | 73.2% | View Chart |
P/BV | x | 3.3 | 4.7 | 71.3% | View Chart |
Dividend Yield | % | 0.7 | 0.6 | 117.4% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
DR. REDDYS LAB Mar-20 |
DISHMAN PHARMA/ DR. REDDYS LAB |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 3,363 | 11.1% | |
Low | Rs | 129 | 2,352 | 5.5% | |
Sales per share (Unadj.) | Rs | 197.8 | 1,054.2 | 18.8% | |
Earnings per share (Unadj.) | Rs | 21.2 | 121.9 | 17.4% | |
Cash flow per share (Unadj.) | Rs | 34.7 | 190.2 | 18.3% | |
Dividends per share (Unadj.) | Rs | 2.00 | 25.00 | 8.0% | |
Dividend yield (eoy) | % | 0.8 | 0.9 | 90.8% | |
Book value per share (Unadj.) | Rs | 179.9 | 938.7 | 19.2% | |
Shares outstanding (eoy) | m | 80.69 | 166.17 | 48.6% | |
Bonus/Rights/Conversions | - | ESOP | - | ||
Price / Sales ratio | x | 1.3 | 2.7 | 46.9% | |
Avg P/E ratio | x | 11.9 | 23.4 | 50.6% | |
P/CF ratio (eoy) | x | 7.2 | 15.0 | 48.2% | |
Price / Book Value ratio | x | 1.4 | 3.0 | 46.0% | |
Dividend payout | % | 9.4 | 20.5 | 46.0% | |
Avg Mkt Cap | Rs m | 20,306 | 474,831 | 4.3% | |
No. of employees | `000 | 0.8 | 21.7 | 3.8% | |
Total wages/salary | Rs m | 5,355 | 33,802 | 15.8% | |
Avg. sales/employee | Rs Th | 19,252.7 | 8,091.0 | 238.0% | |
Avg. wages/employee | Rs Th | 6,459.5 | 1,561.3 | 413.7% | |
Avg. net profit/employee | Rs Th | 2,064.1 | 935.8 | 220.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 175,170 | 9.1% | |
Other income | Rs m | 265 | 6,206 | 4.3% | |
Total revenues | Rs m | 16,226 | 181,376 | 8.9% | |
Gross profit | Rs m | 4,103 | 24,421 | 16.8% | |
Depreciation | Rs m | 1,091 | 11,348 | 9.6% | |
Interest | Rs m | 944 | 983 | 96.1% | |
Profit before tax | Rs m | 2,334 | 18,296 | 12.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1 | 561 | 0.2% | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 624 | -1,403 | -44.4% | |
Profit after tax | Rs m | 1,711 | 20,260 | 8.4% | |
Gross profit margin | % | 25.7 | 13.9 | 184.4% | |
Effective tax rate | % | 26.7 | -7.7 | -348.5% | |
Net profit margin | % | 10.7 | 11.6 | 92.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 125,991 | 8.7% | |
Current liabilities | Rs m | 9,517 | 72,141 | 13.2% | |
Net working cap to sales | % | 9.4 | 30.7 | 30.6% | |
Current ratio | x | 1.2 | 1.7 | 66.3% | |
Inventory Days | Days | 110 | 73 | 151.2% | |
Debtors Days | Days | 35 | 105 | 33.3% | |
Net fixed assets | Rs m | 16,304 | 83,854 | 19.4% | |
Share capital | Rs m | 161 | 831 | 19.4% | |
"Free" reserves | Rs m | 12,907 | 155,157 | 8.3% | |
Net worth | Rs m | 14,516 | 155,988 | 9.3% | |
Long term debt | Rs m | 4,189 | 1,304 | 321.3% | |
Total assets | Rs m | 29,805 | 232,253 | 12.8% | |
Interest coverage | x | 3.5 | 19.6 | 17.7% | |
Debt to equity ratio | x | 0.3 | 0 | 3,452.5% | |
Sales to assets ratio | x | 0.5 | 0.8 | 71.0% | |
Return on assets | % | 8.9 | 9.1 | 97.4% | |
Return on equity | % | 11.8 | 13.0 | 90.8% | |
Return on capital | % | 17.5 | 12.6 | 139.0% | |
Exports to sales | % | 24.8 | 0 | - | |
Imports to sales | % | 3.7 | 0 | - | |
Exports (fob) | Rs m | 3,956 | NA | - | |
Imports (cif) | Rs m | 596 | NA | - | |
Fx inflow | Rs m | 4,952 | 84,193 | 5.9% | |
Fx outflow | Rs m | 697 | 39,616 | 1.8% | |
Net fx | Rs m | 4,255 | 44,577 | 9.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 29,841 | 9.3% | |
From Investments | Rs m | -1,529 | -4,923 | 31.1% | |
From Financial Activity | Rs m | -941 | -25,159 | 3.7% | |
Net Cashflow | Rs m | 316 | -266 | -118.9% |
Indian Promoters | % | 61.4 | 25.5 | 240.8% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 3.7 | 5.4 | 68.5% | |
FIIs | % | 12.7 | 35.3 | 36.0% | |
ADR/GDR | % | 0.0 | 18.5 | - | |
Free float | % | 22.1 | 15.3 | 144.4% | |
Shareholders | 46,261 | 75,885 | 61.0% | ||
Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: JUBILANT PHARMOVA DR. DATSONS LABS WOCKHARDT GSK PHARMA PANACEA BIOTECH
Compare DISHMAN PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Share markets in India are presently trading on a strong note. The BSE Sensex is trading up by 299 points, up 0.6% at 50,739 levels.
Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
This could be the biggest wealth creator of the decade.
In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More